Antibiotic resistance is making it difficult to treat bacterial infections, and new treatment strategies are needed. A new review highlights bacterial extracellular vesicles (BEVs) as promising nanoscale tools that can kill pathogens, block infections, enhance vaccines, and deliver drugs. Researchers have demonstrated how BEVs can be turned into customizable “nanoweapons” by integrating genetic, chemical, and physical engineering. This approach has the potential to reshape infectious disease treatment by enabling safer, more targeted, and more effective alternatives to traditional antibiotics.
Bacterial infections remain a major global health challenge, killing millions of people each year and becoming increasingly resistant to conventional treatments. Antibiotics have long been a cornerstone of infection control, but their overuse and limited targeting ability has accelerated the rise in antibiotic resistance. At the same time, the slow pace of new antibiotic development means that innovative strategies that can effectively prevent and treat infections without causing resistance are urgently needed.
To address this challenge, a research team led by Professor Honggang Hu and Dr. Yejiao Shi of the Institute of Translational Medicine, Shanghai University, China, along with Professor Cuiping Zhang and Dr. Xi Liu, researchers at the People’s Liberation Army General Hospital and the Department of Medical Innovation Research, People’s Liberation Army Medical University in Beijing, China, explored the new potential of bacterial extracellular vesicles (BEVs) as a next-generation therapeutic platform. These nanosized lipid-bound particles are naturally secreted by bacteria, carry bioactive molecules, and can interact with both pathogens and host cells. Their findings were published in the journal Volume 9 on February 5, 2026. the study.
BEVs are of increasing interest due to their unique biological properties. These vesicles, derived from both Gram-negative and Gram-positive bacteria, contain proteins, nucleic acids, metabolites, and pathogen-associated molecular patterns that can influence bacterial competition and host immune responses. Their nanoscale size and membrane structure allow them to penetrate tissues and efficiently deliver molecular cargo, making them highly versatile for biomedical applications.
The researchers emphasize that natural BEV already has inherent antibacterial capabilities. Competing bacteria can be directly killed by delivering enzymes such as autolysins and hydrolytic enzymes that disrupt cell walls and small molecules that inhibit biofilm formation. Furthermore, BEV can interfere with bacterial adhesion to host tissues and prevent infection at an early stage. Their dual role as antibacterial and antiadhesive agents makes them an attractive alternative to traditional antibiotics.
This study outlines a series of engineering strategies to transform BEV into a multifunctional therapeutic tool to further enhance its efficacy. Through genetic engineering, parent bacteria can be modified to produce vesicles with reduced toxicity, increased yield, or enhanced antigen presentation. Physical and chemical methods can be used to load drugs, conjugate target molecules, and conjugate BEVs to nanoparticles. These modifications allow BEV to function not only as an antimicrobial agent but also as a vaccine platform, immune adjuvant, and targeted drug delivery system.
This analysis also revealed how the engineered BEV could address key limitations of existing treatments. As components of vaccines, they can stimulate a strong immune response while avoiding the risks associated with live or attenuated bacteria. As drug carriers, they have the potential to improve antibiotic stability, targeting, and intracellular delivery and overcome resistance mechanisms. ”BEVs combine the benefits of natural biological activity with the flexibility of modern engineering.” Professor Hu Zhang pointed out.This allows for tailoring to a variety of therapeutic needs. ”
Beyond immediate clinical applications, this study points to broader implications for medical and scientific collaboration. In the short term, BEV-based therapies have the potential to improve outcomes for patients with drug-resistant infections and reduce dependence on high-dose antibiotics. In the long term, it could integrate diagnosis, prevention, and treatment into a single platform, enabling a more precise and personalized approach to infection control. ”Integration of bioengineering and emerging technologies such as artificial intelligence will further accelerate the development of BEV-based therapeutics” added Professor Zhang Hu.
In conclusion, despite their promise, several challenges remain. Variability in BEV composition, lack of standardized manufacturing methods, and uncertainties regarding long-term safety must be addressed before widespread use in the clinic. Advances in multi-omics analysis and AI-powered design are expected to play a key role in overcoming these barriers and optimizing BEV performance. As research advances, BEV represents an attractive new frontier in the fight against bacterial infections, offering a flexible, scalable, and potentially transformative alternative to traditional treatments.
sauce:
Science and Technology Review Publishing
Reference magazines:
C, Y, Others. (2026). Manipulating bacterial extracellular vesicles as nanoweapons to fight bacterial infections. the study. DOI: 10.34133/research.1135. https://spj.science.org/doi/10.34133/research.1135
